Compare UPST & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UPST | TMDX |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | 2020 | 2019 |
| Metric | UPST | TMDX |
|---|---|---|
| Price | $28.78 | $71.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 9 |
| Target Price | $45.84 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 4.1M | 1.1M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 131.25 | ★ 382.18 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $1,043,857,000.00 | $605,494,000.00 |
| Revenue This Year | $34.45 | $24.25 |
| Revenue Next Year | $32.64 | $18.75 |
| P/E Ratio | ★ N/A | $371.22 |
| Revenue Growth | ★ 63.99 | 37.13 |
| 52 Week Low | $23.97 | $60.11 |
| 52 Week High | $85.31 | $156.00 |
| Indicator | UPST | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 46.28 |
| Support Level | $25.18 | $64.87 |
| Resistance Level | $30.67 | $80.72 |
| Average True Range (ATR) | 1.72 | 3.04 |
| MACD | -0.59 | 0.28 |
| Stochastic Oscillator | 3.63 | 35.14 |
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The company support development of different lending product offerings, which are grouped into three operating segments - Personal Lending (unsecured personal loans and small dollar loans), Auto Lending (auto refinance, auto retail loans, and auto secured personal loans), and Other (HELOCs and other).
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.